Regn17235
Phase 1
RegeneronRegn17235 is one of 5 therapeutic programs targeting Clonal Cytopenia of Undetermined Significance. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
4
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
4 competitors in Clonal Cytopenia of Undetermined Significance
#DrugCompanyPhaseTrials
1Crestor
AstraZenecaPhase 2
Idhifa
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 2
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 2
Tibsovo
SServier
Phase 2
Regn17235
RegeneronPhase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Regn17235. EMBL-EBI & Wellcome Sanger Institute.
- [3]